Open AccessPrevention by Methylprednisolone of Increased Circulating Tumor Necrosis Factor-alpha Levels and Lung Injury Associated with Systemic Inflammatory Response Syndrome due to Intraperitoneal Hyperthermia
Author(s) -
Megumi Sumida,
Hideo Inaba,
E Isawa,
Shigeru Fujimoto,
Toshihiko Sakurai,
Miwako Kawamata
Publication year - 1999
Publication title -
anesthesia and analgesia/anesthesia and analgesia
Language(s) - English
Resource type - Journals
eISSN - 1526-7598
pISSN - 0003-2999
DOI - 10.1097/00000539-199904000-00017
Subject(s) - medicine , methylprednisolone , tumor necrosis factor alpha , systemic inflammatory response syndrome , lung , perfusion , alpha (finance) , hyperthermia , gastroenterology , anesthesia , sepsis , surgery , construct validity , patient satisfaction
We previously demonstrated that intraperitoneal hyperthermic perfusion (IPHP), which is performed clinically as a treatment for patients with advanced gastrointestinal cancer, can lead to increased serum tumor necrosis factor-alpha (TNF-alpha), systemic inflammatory response syndrome (SIRS), and acute lung injury. Glucocorticoids inhibit the production and actions of TNF-alpha. We investigated whether pretreatment with methylprednisolone (MPS) may modulate serum TNF-alpha and lung injury in patients subjected to IPHP. Serum TNF-alpha was not detected in the patients pretreated with MPS, whereas serum TNF-alpha increased in the control patients (45.7 +/- 8.3 pg/mL, mean +/- SEM) after IPHP. Postoperative lung injury scores were significantly lower in patients pretreated with MPS than in the control patients (P < 0.001).